When do Products Really Peak?
In recent years, many pharmaceutical companies have come to the conclusion that they're not generating enough new products. They anticipate sagging revenues if they go on marketing mostly the same older drugs, figuring that new offerings from competitors will quickly erode sales. But John Ansell, a pharmaceutical consultant based in Thame, near Oxford, UK, thinks companies have been underestimating the sales potential of drugs already on the market.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."